• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病对耐多药结核病治疗结局和长期生存的影响。

Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis.

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

出版信息

Respiration. 2013;86(6):472-8. doi: 10.1159/000348374. Epub 2013 May 8.

DOI:10.1159/000348374
PMID:23689646
Abstract

BACKGROUND

Few studies have investigated the impact of diabetes mellitus (DM), a globally increasing metabolic disease, on treatment outcomes and long-term survival in patients with multidrug-resistant forms of tuberculosis (MDR-TB).

OBJECTIVES

We analyzed outcomes in a large cohort to assess the impact of DM on treatment outcomes of patients with MDR-TB.

METHODS

MDR-TB patients newly diagnosed or retreated between 2000 and 2002 and followed for 8-11 years were retrospectively analyzed with respect to the effect of DM as a comorbidity on their treatment outcome and long-term survival.

RESULTS

Of 1,407 patients with MDR-TB, 239 (17.0%) had coexisting DM. The mean age and body mass index were higher in MDR-TB patients with DM [MDR-TBDM(+)] than in those without DM [MDR-TBDM(-)]. Patients with MDR-TB and a comorbidity of DM had a significantly lower treatment success rate than those without a history of DM (36.0 vs. 47.2%, p = 0.002). In addition, DM was the negative predictor for MDR-TB treatment success in multivariate analyses [odds ratio 0.51, 95% confidence interval (CI) 0.26-0.99]. Mean survival times were also lower in MDR-TBDM(+) than in MDR-TBDM(-) patients (102 vs. 114 months, p = 0.001), with DM as a significant predictor of poor long-term survival in multivariate analyses (hazard ratio 1.59, 95% CI 1.01-2.50).

CONCLUSIONS

Among MDR-TB patients, DM was a relatively common comorbidity. In patients undergoing treatment for MDR-TB and followed for 8-11 years, it was found to be independently associated with an increased risk of both treatment failure and death.

摘要

背景

糖尿病(DM)是一种在全球范围内不断增加的代谢性疾病,鲜有研究调查其对耐多药结核病(MDR-TB)患者的治疗结局和长期生存的影响。

目的

我们分析了一个大型队列的结果,以评估 DM 对 MDR-TB 患者治疗结局的影响。

方法

对 2000 年至 2002 年间新诊断或复治的 MDR-TB 患者进行回顾性分析,研究 DM 作为合并症对其治疗结局和长期生存的影响。

结果

在 1407 例 MDR-TB 患者中,239 例(17.0%)合并 DM。合并 DM 的 MDR-TB 患者的平均年龄和体重指数(BMI)均高于无 DM 的患者(MDR-TBDM(-))。与无 DM 病史的患者相比,合并 DM 的 MDR-TB 患者的治疗成功率显著较低(36.0% vs. 47.2%,p=0.002)。此外,在多变量分析中,DM 是 MDR-TB 治疗成功的负预测因子(比值比 0.51,95%置信区间[CI] 0.26-0.99)。MDR-TBDM(+)患者的平均生存时间也短于 MDR-TBDM(-)患者(102 个月 vs. 114 个月,p=0.001),DM 是多变量分析中不良长期生存的显著预测因子(风险比 1.59,95%CI 1.01-2.50)。

结论

在 MDR-TB 患者中,DM 是一种常见的合并症。在接受 MDR-TB 治疗并随访 8-11 年的患者中,发现 DM 与治疗失败和死亡风险增加独立相关。

相似文献

1
Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis.糖尿病对耐多药结核病治疗结局和长期生存的影响。
Respiration. 2013;86(6):472-8. doi: 10.1159/000348374. Epub 2013 May 8.
2
Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.基于耐药模式的耐多药结核病的治疗结果和生存情况。
Am J Respir Crit Care Med. 2010 Jul 1;182(1):113-9. doi: 10.1164/rccm.200911-1656OC. Epub 2010 Mar 11.
3
Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.广泛耐药结核病患者的治疗结果与长期生存情况
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82. doi: 10.1164/rccm.200801-132OC. Epub 2008 Aug 14.
4
Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.广泛耐药对非HIV感染的耐多药结核病患者治疗结局的影响。
Clin Infect Dis. 2007 Nov 15;45(10):1290-5. doi: 10.1086/522537. Epub 2007 Oct 15.
5
Multidrug-resistant tuberculosis at Srinagarind Hospital, Khon Kaen, Thailand.泰国孔敬府诗里拉吉医院的耐多药结核病
Southeast Asian J Trop Med Public Health. 2002 Sep;33(3):570-4.
6
Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.糖尿病与耐多药结核病的严重不良事件相关。
Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11.
7
Risk Factors for Multidrug-resistant Tuberculosis.耐多药结核病的危险因素
Acta Med Indones. 2018 Jan;50(1):1-2.
8
[The background of drug-resistant tuberculosis patients on the basis of the annual report database for 2007-2009 in Japan].[基于日本2007 - 2009年年报数据库的耐药结核病患者背景情况]
Kekkaku. 2012 Apr;87(4):357-65.
9
[The long term (9-year) survival of multidrug-resistant tuberculosis patients compared to non-multidrug-resistant tuberculosis patients in Henan province].[河南省耐多药结核病患者与非耐多药结核病患者的长期(9年)生存率比较]
Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Feb;34(2):133-6.
10
Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia.糖尿病、吸烟状况与耐多药结核病患者痰培养转阴率:来自格鲁吉亚的队列研究
PLoS One. 2014 Apr 15;9(4):e94890. doi: 10.1371/journal.pone.0094890. eCollection 2014.

引用本文的文献

1
Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment-A Systematic Review and Meta-analysis.撒哈拉以南非洲地区合并症结核病患者的利福平暴露情况:确定治疗人群优先级——系统评价与荟萃分析
Clin Pharmacokinet. 2025 Jul 3. doi: 10.1007/s40262-025-01537-w.
2
Treatment outcomes in people with diabetes and multidrug-resistant tuberculosis (MDR TB) enrolled in the STREAM clinical trial.参与STREAM临床试验的糖尿病合并耐多药结核病(MDR-TB)患者的治疗结果。
PLOS Glob Public Health. 2025 Apr 1;5(4):e0004259. doi: 10.1371/journal.pgph.0004259. eCollection 2025.
3
Survival Probability in Multidrug Resistant Pulmonary Tuberculosis Patients in a South Indian Region.
印度南部地区耐多药肺结核患者的生存概率
Hosp Pharm. 2024 Aug;59(4):427-435. doi: 10.1177/00185787231224065. Epub 2024 Apr 23.
4
Risk factors of MDR-TB and impacts of COVID-19 pandemic on escalating of MDR-TB incidence in lower-middle-income countries: A scoping review.耐多药结核病的风险因素以及2019冠状病毒病大流行对中低收入国家耐多药结核病发病率上升的影响:一项范围综述
Narra J. 2023 Aug;3(2):e220. doi: 10.52225/narra.v3i2.220. Epub 2023 Aug 31.
5
Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis.结核病(TB)-糖尿病共病患者的治疗挑战:系统评价和荟萃分析。
Ann Med. 2024 Dec;56(1):2313683. doi: 10.1080/07853890.2024.2313683. Epub 2024 Feb 12.
6
Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia.体重变化对埃塞俄比亚西北部耐多药结核病患者治疗结局的影响。
Sci Rep. 2024 Jan 4;14(1):508. doi: 10.1038/s41598-023-51026-y.
7
The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis.糖尿病对耐多药结核病的发生和结核病合并糖尿病患者治疗失败的影响:系统评价和荟萃分析。
Front Public Health. 2023 Nov 16;11:1244450. doi: 10.3389/fpubh.2023.1244450. eCollection 2023.
8
Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis.糖尿病影响耐多药结核病的治疗结局:系统评价和荟萃分析。
BMC Infect Dis. 2023 Nov 20;23(1):813. doi: 10.1186/s12879-023-08765-0.
9
Weight variation increases the risk of death during the intensive phase of treatment among MDR-TB patients: A retrospective study.体重变化增加耐多药结核病患者强化治疗阶段的死亡风险:一项回顾性研究。
Pak J Med Sci. 2023 Jul-Aug;39(4):1080-1085. doi: 10.12669/pjms.39.4.7025.
10
Tuberculosis and diabetes mellitus: Relating immune impact of co-morbidity with challenges in disease management in high burden countries.结核病与糖尿病:在高负担国家中,共病的免疫影响与疾病管理挑战之间的关联
J Clin Tuberc Other Mycobact Dis. 2022 Nov 29;29:100343. doi: 10.1016/j.jctube.2022.100343. eCollection 2022 Dec.